Distributor inventory | Tablet

Type 2 diabetes mellitus (post‑prandial/high after-meal blood glucose control), used along with diet, exercise and/or other antidiabetic medicines

Voglibose is an alpha‑glucosidase inhibitor that delays digestion and absorption of carbohydrates in the intestine. This reduces the rise in blood glucose after meals and helps improve overall glycaemic control.

Tablet for oral use. Usually taken just before the start of each main meal (or with the first bite of food) as prescribed. If a meal is skipped, skip the dose. Follow diet/exercise advice and monitor blood glucose.

Flatulence, abdominal pain, diarrhoea, bloating, nausea, constipation, increased liver enzymes (rare)

For type 2 diabetes only; not for diabetic ketoacidosis or type 1 diabetes. Use with caution in patients with inflammatory bowel disease, intestinal obstruction/ulceration, chronic intestinal diseases, severe renal impairment, or liver disease. Risk of hypoglycaemia increases when combined with insulin or sulfonylureas—treat low sugar with glucose (dextrose) rather than sucrose/table sugar. Monitor blood glucose and, if advised, liver enzymes.

Insulin, sulfonylureas and other antidiabetics (increased hypoglycaemia risk), intestinal adsorbents (e.g., activated charcoal) and digestive enzyme preparations (may reduce effect), other drugs that can affect glycaemic control (e.g., corticosteroids, thiazide diuretics, thyroid hormones)

Store below 25°C in a dry place, protected from light and moisture. Keep in original blister pack and out of reach of children.

Voglibose 0.2 mg tablet (generic), Volix 0.2 Tablet, Vobose 0.2 Tablet, Vogli 0.2 Tablet, Voglib 0.2 Tablet